{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T02:18:37Z","timestamp":1769048317075,"version":"3.49.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","fertstert.org","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Fertility and Sterility"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.fertnstert.2024.01.026","type":"journal-article","created":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T16:10:08Z","timestamp":1705767008000},"page":"806-813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Oral medroxyprogesterone acetate for the use of ovulation suppression in in vitro fertilization: a cohort trial"],"prefix":"10.1016","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5888-3342","authenticated-orcid":false,"given":"Annalyn M.","family":"Welp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris D.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura P.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Purcell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linnea R.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.fertnstert.2024.01.026_bib1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.rbmo.2018.12.044","article-title":"Evaluation of the cost-effectiveness of ovulation suppression with progestins compared with GnRH analogs in assisted reproduction cycles","volume":"38","author":"Evans","year":"2019","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.fertnstert.2024.01.026_bib2","first-page":"CD001750","article-title":"Gonadotrophin-releasing hormone antagonists for assisted reproductive technology","author":"Al-Inany","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.fertnstert.2024.01.026_bib3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.fertnstert.2014.04.010","article-title":"Diminished ovarian reserve is the predominant risk factor for gonadotropin-releasing hormone antagonist failure resulting in breakthrough luteinizing hormone surges in in\u00a0vitro fertilization cycles","volume":"102","author":"Reichman","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2024.01.026_bib4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.rbmo.2019.03.212","article-title":"Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era?","volume":"39","author":"La Marca","year":"2019","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.fertnstert.2024.01.026_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.fertnstert.2014.05.027","article-title":"Cryopreservation of human embryos and its contribution to in\u00a0vitro fertilization success rates","volume":"102","author":"Wong","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2024.01.026_bib6","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00404-018-4856-8","article-title":"New trial of progestin-primed ovarian stimulation using dydrogesterone versus a typical GnRH antagonist regimen in assisted reproductive technology","volume":"298","author":"Iwami","year":"2018","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.fertnstert.2024.01.026_bib7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/humupd\/dmaa040","article-title":"Progestins for pituitary suppression during ovarian stimulation for ART: a comprehensive and systematic review including meta-analyses","volume":"27","author":"Ata","year":"2021","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.fertnstert.2024.01.026_bib8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.fertnstert.2015.03.022","article-title":"Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in\u00a0vitro fertilization","volume":"104","author":"Kuang","year":"2015","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2024.01.026_bib9","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.fertnstert.2021.02.036","article-title":"Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial","volume":"116","author":"Giles","year":"2021","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2024.01.026_bib10","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/humrep\/15.7.1490","volume":"15","author":"Borm","year":"2000","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2024.01.026_bib11","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/humrep\/del030","article-title":"Cetrorelix in an oral contraceptive-pretreated stimulation cycle compared with buserelin in IVF\/ICSI patients treated with r-hFSH: a randomized, multicentre, phase IIIb study","volume":"21","author":"Huirne","year":"2006","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2024.01.026_bib12","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/humrep\/dez034","article-title":"Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial","volume":"34","author":"Beguer\u00eda","year":"2019","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2024.01.026_bib13","first-page":"179","article-title":"The role of elagolix in the suppression of ovulation in donor oocyte cycles","volume":"4","author":"Boniface","year":"2023","journal-title":"F S Rep"},{"key":"10.1016\/j.fertnstert.2024.01.026_bib14","first-page":"211","article-title":"New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF","volume":"23","author":"Massin","year":"2017","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.fertnstert.2024.01.026_bib15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.fertnstert.2018.03.022","article-title":"Impact of the levonorgestrel-releasing intrauterine device on controlled ovarian stimulation outcomes","volume":"110","author":"Adeleye","year":"2018","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2024.01.026_bib18","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.fertnstert.2010.11.026","article-title":"Costs of infertility treatment: results from an 18-month prospective cohort study","volume":"95","author":"Katz","year":"2011","journal-title":"Fertil Steril"}],"container-title":["Fertility and Sterility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028224000293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028224000293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T05:38:35Z","timestamp":1746077915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0015028224000293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0015028224000293"],"URL":"https:\/\/doi.org\/10.1016\/j.fertnstert.2024.01.026","relation":{},"ISSN":["0015-0282"],"issn-type":[{"value":"0015-0282","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral medroxyprogesterone acetate for the use of ovulation suppression in in vitro fertilization: a cohort trial","name":"articletitle","label":"Article Title"},{"value":"Fertility and Sterility","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fertnstert.2024.01.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a92024 American Society for Reproductive Medicine, Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}